Shire's Vyvanse wins 1st 'binge-eating' indication
This article was originally published in Scrip
Shire picked up another indication for Vyvanse (lisdexamfetamine dimesylate) – winning the first approval in the US for a drug to help curb episodes of binge-eating in adults with the disorder.
You may also be interested in...
Sunovion must find a new path forward for its dasotraline in attention deficit/hyperactivity disorder (ADHD), following a complete response letter from the US FDA.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.